2024-01-08 07:21:18 ET
DENVER, Colo., Jan. 8, 2023 ( www.247marketnews.com )- Vincerx Pharma, Inc. (NASDAQ: VINC) published, Sunday evening, promising clinical results from a Phase 1 NIH-sponsored study of enitociclib in combination with venetoclax and prednisone for the treatment of relapsed/refractory lymphoma.
Vincerx Pharma is trading at $1.69, up $0.50 (+42.02%), on 4.5M shares traded.
Its 52-week range is $ 0.61 to $1.95. This has a pretty decent chart and is closing in on its 52-week high, on what should be its highest multi-year trading volume, so this should challenge its Spring of 2022 trading levels.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you …
The post Compelling Clinical Results has this One in Deep Green appeared first on 24/7 Market News .
For further details see:
Compelling Clinical Results has this One in Deep Green